Australia Markets close in 5 hrs 27 mins

3 Biotech Stocks Under $15 Worth a Second Look in 2023

3 Biotech Stocks Under $15 Worth a Second Look in 2023

Novavax stands out with its more traditional, protein-based COVID-19 vaccine; MannKind is making a name for itself with inhaled therapies for diabetics and patients with lung disorders; and Anavex has a promising Alzheimer's therapy.